Comparison and screening of different risk assessment models for deep vein thrombosis in patients with solid tumors

被引:22
作者
Wang, Meng-meng [1 ]
Qin, Xiao-juan [2 ,3 ]
He, Xiao-xiao [1 ]
Qiu, Meng-jun [1 ]
Peng, Gang [4 ]
Yang, Sheng-li [4 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Liyuan Hosp, Div Gastroenterol, Wuhan 430077, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Dept Ultrasound, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China
[3] Hubei Prov Key Lab Mol Imaging, Wuhan 430022, Hubei, Peoples R China
[4] Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, 1277 JieFang Ave, Wuhan 430022, Hubei, Peoples R China
关键词
DVT; Pauda; Khorana; Solid tumor; Risk prediction; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; CANCER; CHEMOTHERAPY; PREDICTION; VALIDATION; EVENTS;
D O I
10.1007/s11239-019-01840-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To increase the detection rate of deep vein thrombosis (DVT) and to compare the predictive value of four different risk assessment scales (Caprini, Autar, Pauda, and Khorana scales) for DVT in patients with solid tumors by the receiver operating curve (ROC). A total of 361 patients with all kinds of malignant solid tumors, who accepted anti-tumor therapy in the cancer center between March 3, 2015 to April 13, 2018, were assigned to a group of 230 cases diagnosed with DVT and a control group of 131 cases without DVT. Data were recorded and summarized, and the predictive value of the above four risk assessment scales for DVT in solid tumor patients was compared based on the area under the ROC curve (AUC). The AUC values determined for the Caprini, Autar, Pauda, and Khorana scales were (0.631 +/- 0.030), (0.686 +/- 0.028), (0.654 +/- 0.029), and (0.599 +/- 0.032), respectively; maximum sensitivity, specificity, and Youden index were 80.9% for Khorana, 86.3% for Caprini, and 29.6% for Autar scale, respectively. We found no statistically significant differences in the AUC values between Autar and Caprini, Autar and Khorana, as well as Khorana and Pauda (p>0.05). However, the AUC differences between Autar and Pauda, Caprini and Khorana, as well as Caprini and Pauda were statistically significant (p<0.05). All four risk assessment models showed some value in the risk prediction of DVT in patients with solid tumors, but every model also exhibited its own restrictions; maximum sensitivity, specificity, and Youden index were 80.9% for Khorana, 86.3% for Caprini, and 29.6% for Autar scale, respectively. We confirmed that the detection rate can be improved by modifying the BMI cut-off value of the scale or by combining appropriate scales.
引用
收藏
页码:292 / 298
页数:7
相关论文
共 26 条
[1]  
Autar R., 2003, J. Orthop. Nurs., V7, P114, DOI [10.1016/S1361-3111(03)00051-7, DOI 10.1016/S1361-3111(03)00051-7]
[2]   Cancer-associated venous thromboembolism: Burden, mechanisms, and management [J].
Ay, Cihan ;
Pabinger, Ingrid ;
Cohen, Alexander T. .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) :219-230
[3]   A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method [J].
Bahl, Vinita ;
Hu, Hsou Mei ;
Henke, Peter K. ;
Wakefield, Thomas W. ;
Campbell, Darrell A., Jr. ;
Caprini, Joseph A. .
ANNALS OF SURGERY, 2010, 251 (02) :344-350
[4]   A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score [J].
Barbar, S. ;
Noventa, F. ;
Rossetto, V. ;
Ferrari, A. ;
Brandolin, B. ;
Perlati, M. ;
De Bon, E. ;
Tormene, D. ;
Pagnan, A. ;
Prandoni, P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (11) :2450-2457
[5]   Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy [J].
Cavo, M ;
Zamagni, E ;
Cellini, C ;
Tosi, P ;
Cangini, D ;
Cini, M ;
Valdrè, L ;
Palareti, G ;
Masini, L ;
Tura, S ;
Baccarani, M .
BLOOD, 2002, 100 (06) :2272-2273
[6]   Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study [J].
Dentali, F. ;
Pegoraro, S. ;
Barco, S. ;
Di Minno, M. N. D. ;
Mastroiacovo, D. ;
Pomero, F. ;
Lodigiani, C. ;
Bagna, F. ;
Sartori, M. ;
Barillari, G. ;
Mumoli, N. ;
Napolitano, M. ;
Passamonti, S. M. ;
Benedetti, R. ;
Ageno, W. ;
Di Nisio, M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (09) :1757-1763
[7]   Arterial thrombosis in ambulatory cancer patients treated with chemotherapy [J].
Di Nisio, Marcello ;
Ferrante, Noemi ;
Feragalli, Beatrice ;
De Tursi, Michele ;
Iacobelli, Stefano ;
Cuccurullo, Franco ;
Porreca, Ettore .
THROMBOSIS RESEARCH, 2011, 127 (04) :382-383
[8]   Cancer-Associated Venous Thromboembolism [J].
Elewa H. ;
Elrefai R. ;
Barnes G.D. .
Current Treatment Options in Cardiovascular Medicine, 2016, 18 (4) :1-9
[9]   Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism [J].
Faiz, Ambarina S. ;
Khan, Imran ;
Beckman, Michele G. ;
Bockenstedt, Paula ;
Heit, John A. ;
Kulkarni, Roshni ;
Manco-Johnson, Marilyn ;
Moll, Stephan ;
Ortel, Thomas L. ;
Philipp, Claire S. .
THROMBOSIS RESEARCH, 2015, 136 (03) :535-541
[10]   Coagulation and cancer: biological and clinical aspects [J].
Falanga, A. ;
Marchetti, M. ;
Vignoli, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (02) :223-233